Why did 1AD.AX stock drop 33% on 20 Feb 2026?

The one-day fall to A$0.003 was driven by heavy selling and thin liquidity. Volume hit **20,375,003** shares. No major regulatory news was released; markets are pricing event and funding risk ahead of the 2026-03-02 company update

What are the main risks for 1AD.AX stock holders?

Primary risks include adverse clinical results, the need for capital raising that could dilute shareholders, and low liquidity given market cap **A$522,238**. Financial metrics show negative operating cash flow and limited runway

What price target does Meyka AI have for 1AD.AX stock?

Meyka AI's model projects a 12-month base case target of **A$0.008**, implying **+166.67%** from A$0.003. Forecasts are model-based projections and not guarantees

How should traders monitor 1AD.AX stock in the near term?

Focus on the scheduled company announcement on **2026-03-02**, daily volume spikes, and any capital market activity. Use small position sizes and limit orders due to high volatility and thin depth

AU Stocks

1AD.AX stock falls 33% to A$0.003 on 20 Feb 2026 ASX: what traders must watch

ByHuzaifa Zahoor February 20, 2026February 20, 2026

The 1AD.AX stock price plunged 33.33% to A$0.003 at the ASX close on 20 Feb 2026, trading 20,375,003 shares as sellers dominated the session. This sharp drop followed an earlier intraday high of A$0.004 and leaves the share price close to its year low A$0.002. Investors reacted to thin market depth, weak biotech sentiment in healthcare, and an upcoming company announcement dated 2026-03-02. We summarise price drivers, valuation metrics, technical context and what to monitor next for AdAlta Limited (1AD.AX) on the ASX in Australia